Q3 result preview: US, India to aid revenue growth for Pharma Inc

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for......

India Inc's profit-to-GDP ratio dips slightly in FY23; financial pie up

Corporate India’s net profit as a percentage of gross domestic product (GDP) dipped in the 2022-23 financial year (FY23) -- after rebounding sharply in FY22 -- amid a decline in global......

India Inc's capex wheel likely to turn soon

India Inc could be embarking upon a new phase of capital expenditure (capex) cycle, observed analysts, and suggest its revival would lead to a rerating of industrial stocks. Illustration: Dominic......

'We prefer stocks likely to gain from strong domestic growth potential'

'We like certain stocks from banking, insurance, retail, hospitals and capital goods.''Though some of these stocks may seem expensive, they will compound well over the long term, thus justifying......